News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Commentaries
Subscribe

Spotlight -

Our July 2026 issue|

2026 State of Pharmacy survey results available now|

Free Webinar: The Great 340B Debate

Opinion|Videos|October 16, 2025

Introducing the EMERALD Trial

Author(s)Daphne Stewart, MD, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO

The EMERALD trial evaluated elacestrant, an oral SERD, as a potential new standard for patients with ER+/HER2– advanced breast cancer resistant to prior endocrine therapies.

Episodes in this series

EP. 1 Introducing the EMERALD Trial

EP. 1 Introducing the EMERALD Trial

EP. 2 Examining Therapies Used in Later Lines of Treatment in ER+/HER2- Metastatic Breast Cancer

EP. 2 Examining Therapies Used in Later Lines of Treatment in ER+/HER2- Metastatic Breast Cancer

EP. 3 Unmet Needs in Patients with ER+/HER2- Metastatic Breast Cancer with an ESR1 Mutation

EP. 3 Unmet Needs in Patients with ER+/HER2- Metastatic Breast Cancer with an ESR1 Mutation

EP. 4 Treatment Sequencing of ER+/HER2- Metastatic Breast Cancer and the Associated Healthcare Resource Utilization and Overall Cost of Care

EP. 4 Treatment Sequencing of ER+/HER2- Metastatic Breast Cancer and the Associated Healthcare Resource Utilization and Overall Cost of Care

EP. 5 Emerald Trial Study Design Strengths and Limitations

EP. 5 Emerald Trial Study Design Strengths and Limitations

EP. 6 Baseline Characteristics of the Emerald Trial and the Importance of an ESR1 Mutation

EP. 6 Baseline Characteristics of the Emerald Trial and the Importance of an ESR1 Mutation

EP. 7 Additional Baseline Characteristics and Their Relevance to Clinical Practice

EP. 7 Additional Baseline Characteristics and Their Relevance to Clinical Practice

EP. 8 Evaluating Efficacy and Safety Data from the EMERALD Trial

EP. 8 Evaluating Efficacy and Safety Data from the EMERALD Trial

EP. 9 Implications of the EMERALD Study for Patients, Providers, and Payers

EP. 9 Implications of the EMERALD Study for Patients, Providers, and Payers

EP. 10 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD Trial

EP. 10 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD Trial

EP. 11 Subgroup Analysis From the Phase 3 EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor

EP. 11 Subgroup Analysis From the Phase 3 EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor

EP. 12 Beyond the Primary End Point: Diving Deeper Into the EMERALD trial | Written Recap

EP. 12 Beyond the Primary End Point: Diving Deeper Into the EMERALD trial | Written Recap

The EMERALD trial is a pivotal phase 3 study evaluating elacestrant, an oral selective estrogen receptor degrader, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.

The trial sought to determine whether elacestrant could offer improved outcomes over standard endocrine therapies. It specifically addressed treatment-resistant cases that had previously received endocrine therapy and CDK4/6 inhibitors, representing a significant unmet clinical need in metastatic breast cancer management.

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

July 3rd 2026

From Clinical Trials to Community Practice: Contextualizing Lorlatinib's Durability and Implementing Long-Term Management Strategies

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 26th 2026

Managing Lorlatinib's Unique Safety Profile: Dose Optimization and Practical Strategies for Long-Term Tolerability

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 26th 2026

Interpreting CROWN's Key Efficacy Outcomes: PFS Milestones, Survival Probabilities, and the Overall Survival Story

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 19th 2026

The CROWN Study: Design, Context, and the Clinical Significance of 7-Year Follow-Up Data

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 19th 2026

Latest CME

27th Annual International Lung Cancer Congress®

In-Person + Virtual Event

27th Annual International Lung Cancer Congress®

July 24-25, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Luis Paz-Ares, MD, PhD; Jacob Sands, MD

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on Managed Healthcare Executive

Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care

Loss of copay assistance linked to worse outcomes in retina patients | ASRS 2026

Step therapy requirements drive up time, costs in DME patients | ASRS 2026

Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes

A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk